Here it was hypothesized that by replacing the C2 toxin binding domain with a C. botulinum neurotoxin (BoNT) serotype C1 binding domain (C1 HCC), the engineered B domain and payload could be expressed separately, combined and enable targeting of neural cells, while preserving the normal C2 translocation process. Here, C2 is linked to hepatocellular carcinoma.